drugset / Trial / NCT06143735
A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors
Phase 2
Unknown
99 enrolled
Tianjin Medical University Cancer Institute and Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study was to observe the efficacy and safety of Efbemalenograstim Alfa in the prevention of absolute neutrophil count (ANC) reduction after chemotherapy in NSCLC patients at risk of platinum-containing chemotherapy with risk factors in febrile neutropenia (FN)
Timeline
- Start
- 2023-12-31
- Primary completion
- 2024-12-31
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efgbemalenograstim alfa | Protein / enzyme biologic | 20 mg | Subcutaneous |